SEARCH

SEARCH BY CITATION

References

  • 1
    Van den Berge M, Ten Hacken NHT, Cohen J, Douma WR, Postma DS. Small airway disease in asthma and COPD: clinical implications. Chest 2011;139:412423.
  • 2
    Virchow JC. Asthma–a small airway disease: concepts and evidence. Pneumologie 2009;63(Suppl 2):S96S101.
  • 3
    Mead J. The lung's “quiet zone”. N Engl J Med 1970;282:13181319.
  • 4
    Wagner EM, Liu MC, Weinmann GG, Permutt S, Bleecker ER. Peripheral lung resistance in normal and asthmatic subjects. Am Rev Respir Dis 1990;141:584588.
  • 5
    Kraft M, Pak J, Martin RJ, Kaminsky D, Irvin CG. Distal lung dysfunction at night in nocturnal asthma. Am J Respir Crit Care Med 2001;163:15511556.
  • 6
    Kaminsky DA, Irvin CG, Gurka DA, Feldsien DC, Wagner EM, Liu MC et al. Peripheral airways responsiveness to cool, dry air in normal and asthmatic individuals. Am J Respir Crit Care Med 1995;152:17841790.
  • 7
    Zeidler MR, Goldin JG, Kleerup EC, Kim HJ, Truong DA, Gjertson DW et al. Small airways response to naturalistic cat allergen exposure in subjects with asthma. J Allergy Clin Immunol 2006;118:10751081.
  • 8
    In ‘t Veen JC, Beekman AJ, Bel EH, Sterk PJ. Recurrent exacerbations in severe asthma are associated with enhanced airway closure during stable episodes. Am J Respir Crit Care Med 2000;161:19021906.
  • 9
    Lee P, Abisheganaden J, Chee CB, Wang YT. A new asthma severity index: a predictor of near-fatal asthma? Eur Respir J 2001;18:272278.
  • 10
    Gibbons WJ, Sharma A, Lougheed D, Macklem PT. Detection of excessive bronchoconstriction in asthma. Am J Respir Crit Care Med 1996;153:582589.
  • 11
    Yu J, Yoo Y, Kim DK, Koh YY. The relationship between delta-forced vital capacity (percent fall in forced vital capacity at the PC20 dose of methacholine) and the maximal airway response in patients who have mild asthma. Allergy Asthma Proc 2005;26:366372.
  • 12
    Hogg JC, McDonough JE, Gosselink JV, Hayashi S. What drives the peripheral lung-remodeling process in chronic obstructive pulmonary disease? Proc Am Thorac Soc 2009;6:668672.
  • 13
    Saetta M, Di SA, Rosina C, Thiene G, Fabbri LM. Quantitative structural analysis of peripheral airways and arteries in sudden fatal asthma. Am Rev Respir Dis 1991;143:138143.
  • 14
    Carroll N, Cooke C, James A. The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. Eur Respir J 1997;10:292300.
  • 15
    Kuwano K, Bosken CH, Pare PD, Bai TR, Wiggs BR, Hogg JC. Small airways dimensions in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 1993;148:12201225.
  • 16
    Hamid Q, Song Y, Kotsimbos TC, Minshall E, Bai TR, Hegele RG et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 1997;100:4451.
  • 17
    Carroll N, Carello S, Cooke C, James A. Airway structure and inflammatory cells in fatal attacks of asthma. Eur Respir J 1996;9:709715.
  • 18
    De Magalhaes SS, dos Santos MA, da Silva OM, Fontes ES, Fernezlian S, Garippo AL et al. Inflammatory cell mapping of the respiratory tract in fatal asthma. Clin Exp Allergy 2005;35:602611.
  • 19
    Haley KJ, Sunday ME, Wiggs BR, Kozakewich HP, Reilly JJ, Mentzer SJ et al. Inflammatory cell distribution within and along asthmatic airways. Am J Respir Crit Care Med 1998;158:565572.
  • 20
    Faul JL, Tormey VJ, Leonard C, Burke CM, Farmer J, Horne SJ et al. Lung immunopathology in cases of sudden asthma death. Eur Respir J 1997;10:301307.
  • 21
    Balzar S, Chu HW, Strand M, Wenzel S. Relationship of small airway chymase-positive mast cells and lung function in severe asthma. Am J Respir Crit Care Med 2005;171:431439.
  • 22
    Van Vyve T, Chanez P, Lacoste JY, Bousquet J, Michel FB, Godard P. Comparison between bronchial and alveolar samples of bronchoalveolar lavage fluid in asthma. Chest 1992;102:356361.
  • 23
    Vignola AM, Chanez P, Campbell AM, Souques F, Lebel B, Enander I et al. Airway inflammation in mild intermittent and in persistent asthma. Am J Respir Crit Care Med 1998;157:403409.
  • 24
    Lehtimaki L, Kankaanranta H, Saarelainen S, Turjanmaa V, Moilanen E. Increased alveolar nitric oxide concentration in asthmatic patients with nocturnal symptoms. Eur Respir J 2002;20:841845.
  • 25
    Brindicci C, Ito K, Barnes PJ, Kharitonov SA. Differential flow analysis of exhaled nitric oxide in patients with asthma of differing severity. Chest 2007;131:13531362.
  • 26
    Takeda T, Oga T, Niimi A, Matsumoto H, Ito I, Yamaguchi M et al. Relationship between small airway function and health status, dyspnea and disease control in asthma. Respiration 2010;80:120126.
  • 27
    Van Veen I, Sterk PJ, Schot R, Gauw SA, Rabe KF, Bel EH. Alveolar nitric oxide versus measures of peripheral airway dysfunction in severe asthma. Eur Respir J 2006;27:951956.
  • 28
    Farah CS, King GG, Brown NJ, Downie SR, Kermode JA, Hardaker KM et al. The role of the small airways in the clinical expression of asthma in adults. J Allergy Clin Immunol 2012;129:381387.
  • 29
    Sorkness RL, Bleecker ER, Busse WW, Calhoun WJ, Castro M, Chung KF et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol 2008;104:394403.
  • 30
    Kiers A, van der Mark TW, Woldring MG, Peset R. Changes in functional residual capacity during exercise in patients with exercise-induced asthma. Bull Eur Physiopathol Respir 1981;17:869878.
  • 31
    Goldin JG, Nitt-Gray MF, Sorenson SM, Johnson TD, Dauphinee B, Kleerup EC et al. Airway hyperreactivity: assessment with helical thin-section CT. Radiology 1998;208:321329.
  • 32
    Beigelman-Aubry C, Capderou A, Grenier PA, Straus C, Becquemin MH, Similowski T et al. Mild intermittent asthma: CT assessment of bronchial cross-sectional area and lung attenuation at controlled lung volume. Radiology 2002;223:181187.
  • 33
    Vikgren J, Bake B, Ekberg-Jansson A, Larsson S, Tylen U. Value of air trapping in detection of small airways disease in smokers. Acta Radiol 2003;44:517524.
  • 34
    Bauman G, Scholz A, Rivoire J, Terekhov M, Friedrich J, de OA et al. Lung ventilation- and perfusion-weighted Fourier decomposition magnetic resonance imaging: in vivo validation with hyperpolarized (3) He and dynamic contrast-enhanced MRI. Magn Reson Med 2012; [Epub ahead of print].
  • 35
    Carvalho TC, Peters JI, Williams RO III. Influence of particle size on regional lung deposition–what evidence is there? Int J Pharm 2011;406:110.
  • 36
    Leach CL. Improved delivery of inhaled steroids to the large and small airways. Respir Med 1998;92(Suppl A):38.
  • 37
    Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest 2002;122:510516.
  • 38
    Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006;100:375384.
  • 39
    Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med 2005;172:14971504.
  • 40
    Barnes PJ. Distribution of receptor targets in the lung. Proc Am Thorac Soc 2004;1:345351.
  • 41
    Adcock IM, Gilbey T, Gelder CM, Chung KF, Barnes PJ. Glucocorticoid receptor localization in normal and asthmatic lung. Am J Respir Crit Care Med 1996;154:771782.
  • 42
    Zanen P, Go LT, Lammers JW. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 1996;51:977980.
  • 43
    Busse WW, Brazinsky S, Jacobson K, Stricker W, Schmitt K, Vanden BJ et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999;104:12151222.
  • 44
    Yamaguchi M, Niimi A, Ueda T, Takemura M, Matsuoka H, Jinnai M et al. Effect of inhaled corticosteroids on small airways in asthma: investigation using impulse oscillometry. Pulm Pharmacol Ther 2009;22:326332.
  • 45
    Goldin JG, Tashkin DP, Kleerup EC, Greaser LE, Haywood UM, Sayre JW et al. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J Allergy Clin Immunol 1999;104:S258S267.
  • 46
    Thongngarm T, Silkoff PE, Kossack WS, Nelson HS. Hydrofluoroalkane-134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma. J Asthma 2005;42:257263.
  • 47
    Hauber H, Taha R, Bergeron C, Migounov V, Hamid Q, Olivenstein R. Effects of hydrofluoroalkane and dry powder-formulated corticosteroids on sputum inflammatory markers in asthmatic patients. Can Respir J 2006;13:7378.
  • 48
    Bateman ED, Linnhof AE, Homik L, Freudensprung U, Smau L, Engelstatter R. Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma. Pulm Pharmacol Ther 2008;21:264275.
  • 49
    Buhl R, Vinkler I, Magyar P, Gyori Z, Rybacki C, Middle MV et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulm Pharmacol Ther 2006;19:404412.
  • 50
    Ukena D, Biberger C, Steinijans V, von BV, Malek R, Weber HH et al. Ciclesonide is more effective than budesonide in the treatment of persistent asthma. Pulm Pharmacol Ther 2007;20:562570.
  • 51
    Boulet LP, Drollmann A, Magyar P, Timar M, Knight A, Engelstatter R et al. Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma. Respir Med 2006;100:785794.
  • 52
    Zietkowski Z, Bodzenta-Lukaszyk A, Tomasiak MM, Szymanski W, Skiepko R. Effect of ciclesonide and fluticasone on exhaled nitric oxide in patients with mild allergic asthma. Respir Med 2006;100:16511656.
  • 53
    Boulet LP, Bateman ED, Voves R, Muller T, Wolf S, Engelstatter R. A randomized study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma. Respir Med 2007;101:16771686.
  • 54
    Cohen J, Douma WR, Ten Hacken NH, Vonk JM, Oudkerk M, Postma DS. Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J 2008;31:12131220.
  • 55
    Hoshino M. Comparison of effectiveness in ciclesonide and fluticasone propionate on small airway function in mild asthma. Allergol Int 2010;59:5966.
  • 56
    Cohen J, Postma DS, Douma WR, Vonk JM, De Boer AH, Ten Hacken NH. Particle size matters: diagnostics and treatment of small airways involvement in asthma. Eur Respir J 2011;37:532540.
  • 57
    Wurthwein G, Rohdewald P. Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate. Biopharm Drug Dispos 1990;11:381394.
  • 58
    Thompson PJ, Davies RJ, Young WF, Grossman AB, Donnell D. Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol. Respir Med 1998;92(Suppl A):3339.
  • 59
    Harrison LI, Colice GL, Donnell D, Soria I, Dockhorn R. Adrenal effects and pharmacokinetics of CFC-free beclomethasone dipropionate: a 14-day dose-response study. J Pharm Pharmacol 1999;51:263269.
  • 60
    Mutch E, Nave R, McCracken N, Zech K, Williams FM. The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochem Pharmacol 2007;73:16571664.
  • 61
    Richter K, Kanniess F, Biberger C, Nave R, Magnussen H. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol 2005;45:146152.
  • 62
    Nave R, Zech K, Bethke TD. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol 2005;61:203208.
  • 63
    Rohatagi S, Luo Y, Shen L, Guo Z, Schemm C, Huang Y et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther 2005;12:201209.
  • 64
    Lipworth BJ, Kaliner MA, LaForce CF, Baker JW, Kaiser HB, Amin D et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 2005;94:465472.
  • 65
    Derom E, Van De Velde V, Marissens S, Engelstätter R, Vincken W, Pauwels R. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′-monophosphate in asthmatic patients. Pulm Pharmacol Ther 2005;18:328336.
  • 66
    Van den Berge M, Arshad SH, Ind PW, Magnussen H, Hamelmann E, Kanniess F et al. Similar efficacy of ciclesonide versus prednisolone to treat asthma worsening after steroid tapering. Respir Med 2009;103:12161223.
  • 67
    Vermeulen JH, Gyurkovits K, Rauer H, Engelstatter R. Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respir Med 2007;101:21822191.
  • 68
    Von Berg A, Engelstatter R, Minic P, Sreckovic M, Garcia Garcia ML, Latos T et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily vs. budesonide 400 microg once daily in children with asthma. Pediatr Allergy Immunol 2007;18:391400.
  • 69
    Van der Molen T, Foster JM, Caeser M, Muller T, Postma DS. Difference between patient-reported side effects of ciclesonide versus fluticasone propionate. Respir Med 2010;104:18251833.
  • 70
    Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:588599.
  • 71
    Dempsey OJ, Fowler SJ, Wilson A, Kennedy G, Lipworth BJ. Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. Chest 2002;122:151159.
  • 72
    Cohen J, Postma DS, Vink-Klooster K, van der BW, Verschuuren E, Ten Hacken NH et al. FVC to slow inspiratory vital capacity ratio: a potential marker for small airways obstruction. Chest 2007;132:11981203.
  • 73
    Lucidarme O, Coche E, Cluzel P, Mourey-Gerosa I, Howarth N, Grenier P. Expiratory CT scans for chronic airway disease: correlation with pulmonary function test results. AJR Am J Roentgenol 1998;170:301307.
  • 74
    Gelb AF, Taylor CF, Nussbaum E, Gutierrez C, Schein A, Shinar CM et al. Alveolar and airway sites of nitric oxide inflammation in treated asthma. Am J Respir Crit Care Med 2004;170:737741.
  • 75
    Goldman MD, Carter R, Klein R, Fritz G, Carter B, Pachucki P. Within- and between-day variability of respiratory impedance, using impulse oscillometry in adolescent asthmatics. Pediatr Pulmonol 2002;34:312319.
  • 76
    King GG, Downie SR, Verbanck S, Thorpe CW, Berend N, Salome CM et al. Effects of methacholine on small airway function measured by forced oscillation technique and multiple breath nitrogen washout in normal subjects. Respir Physiol Neurobiol 2005;148:165177.
  • 77
    Verbanck S, Schuermans D, Vincken W. Inflammation and airway function in the lung periphery of patients with stable asthma. J Allergy Clin Immunol 2010;125:611616.
  • 78
    Gershman NH, Liu H, Wong HH, Liu JT, Fahy JV. Fractional analysis of sequential induced sputum samples during sputum induction: evidence that different lung compartments are sampled at different time points. J Allergy Clin Immunol 1999;104:322328.
  • 79
    Sutherland ER, Martin RJ, Bowler RP, Zhang Y, Rex MD, Kraft M. Physiologic correlates of distal lung inflammation in asthma. J Allergy Clin Immunol 2004;113:10461050.
  • 80
    De Vries TW, Rottier BL, Gjaltema D, Hagedoorn P, Frijlink HW, De Boer AH. Comparative in vitro evaluation of four corticosteroid metered dose inhalers: consistency of delivered dose and particle size distribution. Respir Med 2009;103:11671173.
  • 81
    Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998;157:S1S53.